ArticleTherapeutic advances in neurological disorders2024

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.

Helmut Butzkueven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.